Neuroscience and biobehavioral reviews · 2026
Prevalence and clinical correlates of cocaine use disorder among patients diagnosed with bipolar disorder: A systematic review, meta-analysis, and meta-regression.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Aguiar Kyara Rodrigues, Zimmer Camila, Kampmann Luiza, Caobelli Anna Clara Sarmento Leite, Chagas Vinicius, Jansen Karen, Cardoso Taiane Azevedo, Kapczinski Flávio, Pinto Jairo Vinícius, Passos Ives Cavalcante
Аннотация
INTRODUCTION: Substance Use Disorders (SUD) are among the most common comorbidities in individuals with Bipolar Disorder (BD). However, the prevalence of cocaine use disorder (CUD) and its impact on the clinical course of BD have not been extensively explored and synthesized to date.
OBJECTIVE: To estimate the prevalence of CUD among individuals with BD and describe its associated clinical correlates.
METHODS: We conducted a systematic review with meta-analysis and meta-regression following PRISMA guidelines. Six databases were searched through December 2024. We included observational studies reporting CUD prevalence or clinical comparisons between BD individuals with and without CUD. Risk of bias was assessed using the Newcastle-Ottawa Scale. A random-effects model was used for meta-analyses.
RESULTS: Twenty-seven studies comprising 6150,881 individuals with BD were included in the meta-analysis. The pooled overall prevalence of CUD in BD was 10.94% (95% CI: 6.15-18.73), rising to 46.25% (95% CI: 34.77-58.15) in studies including primary SUD samples; heterogeneity across studies was high. Seven studies were included in the qualitative synthesis of clinical correlates. BD+CUD individuals showed worse affective symptoms, higher rates of psychiatric comorbidities (e.g., post-traumatic stress disorder, attention-deficit/hyperactivity disorder), polysubstance use, and lower medication adherence compared to BD individuals without comorbid CUD. Sociodemographic vulnerability and increased risk behaviors were also more frequent. Although cognitive performance was broadly similar, BD+CUD patients performed slightly better than BD+AUD in delayed recall, possibly reflecting substance-specific effects.
CONCLUSION: CUD is common among individuals with BD and is associated with more severe clinical profiles. Findings highlight the need for integrated treatment strategies and greater clinical attention to this comorbidity.
OBJECTIVE: To estimate the prevalence of CUD among individuals with BD and describe its associated clinical correlates.
METHODS: We conducted a systematic review with meta-analysis and meta-regression following PRISMA guidelines. Six databases were searched through December 2024. We included observational studies reporting CUD prevalence or clinical comparisons between BD individuals with and without CUD. Risk of bias was assessed using the Newcastle-Ottawa Scale. A random-effects model was used for meta-analyses.
RESULTS: Twenty-seven studies comprising 6150,881 individuals with BD were included in the meta-analysis. The pooled overall prevalence of CUD in BD was 10.94% (95% CI: 6.15-18.73), rising to 46.25% (95% CI: 34.77-58.15) in studies including primary SUD samples; heterogeneity across studies was high. Seven studies were included in the qualitative synthesis of clinical correlates. BD+CUD individuals showed worse affective symptoms, higher rates of psychiatric comorbidities (e.g., post-traumatic stress disorder, attention-deficit/hyperactivity disorder), polysubstance use, and lower medication adherence compared to BD individuals without comorbid CUD. Sociodemographic vulnerability and increased risk behaviors were also more frequent. Although cognitive performance was broadly similar, BD+CUD patients performed slightly better than BD+AUD in delayed recall, possibly reflecting substance-specific effects.
CONCLUSION: CUD is common among individuals with BD and is associated with more severe clinical profiles. Findings highlight the need for integrated treatment strategies and greater clinical attention to this comorbidity.